Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Nuevos compuestos inmunoestimulantes sintéticos para el tratamiento de la leishmaniasis y tuberculosis

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20180226001
Publicado:
09/03/2018
Caducidad:
10/03/2019
Resumen:
Un instituto de investigación alemán con amplia experiencia en enfermedades tropicales y enfermedades infecciosas emergentes ha desarrollado nuevos compuestos inmunoestimulantes para el tratamiento eficaz de enfermedades infecciosas intracelulares, como la tuberculosis y leishmaniasis. Los nuevos compuestos inmunoestimulantes se basan en moléculas glicolipídicas activas aisladas de la Entamoeba histolytica, y su actividad antiinfecciosa ha sido probada in vivo en ratones e in vitro con macrófagos murino y humanos con éxito. Los resultados son prometedores y han demostrado una estimulación eficiente de la respuesta inmunológica, la inducción segura de citoquinas favorables y un mayor rendimiento y menos efectos secundarios que los tratamientos actuales. El instituto busca socios de las industrias farmacéutica y veterinaria para establecer acuerdos de licencia, I+D y cesión de derechos.

Details

Tittle:
New immunostimulatory synthetic compounds for the treatment of leishmaniasis and tuberculosis
Summary:
A German research institution developed novel immunostimulatory compounds for effective treatment of intracellular infectious diseases like tuberculosis and leishmaniasis. Transfer of rights, license agreements or R-Y-D cooperation are offered to industrial partners from pharmaceutical or animal health industry.
Description:
Tuberculosis and leishmaniasis belong to the world´s deadliest infectious diseases with several millions of new infections per year. The current treatment options are insufficient due to long, systemic treatment durations, toxic side effects and high treatment costs. Moreover, they bear the risk of the induction of resistances. New well-tolerated and effective compounds are needed which are able to activate or restimulate the otherwise insufficient immune response in patients.

A German research institution with high expertise in the field of tropical diseases and emerging infections has developed an alternative treatment of intracellular infections such as tuberculosis and leishmaniasis based on synthetic immune activators. Application can be both in human and in veterinary sector. The novel immunostimulatory compounds are based on active glycolipid molecules isolated from Entamoeba histolytica. They have been successfully tested with regard to their anti-infective activity in vivo in mice (ongoing) and in vitro with murine and human macrophages. Tests on compound administration using nanocarriers are ongoing. Test results are very promising and show:
- Efficient stimulation of the immune response
- Reliable induction of favourable cytokines
- Better performance and less side effects than current treatment options.

A patent application has been filed. The research institution is searching for contacts to industrial partners from pharmaceutical or animal health industry offering license agreements or transfer of rights. This can be complemented by R-Y-D cooperation on common further development towards medical approval.
Advantages and Innovations:
- Well-tolerated and effective compound for treatment of intracellular infections

- Better performance and less side effects compared to current treatment options

- Developed by renowned experts
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Several national Patent Applications filed

Partner sought

Type and Role of Partner Sought:
Partners sought are pharmaceutical manufacturers active in human or veterinary medicine interested in development and commercialisation of drugs for treatment of infectious diseases like tuberculosis and leishmaniasis.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German
Spanish

Keywords

Technology Keywords:
06001012 Investigaciones médicas
07001009 Medicina veterinaria
06001 Medicina, salud humana
03004007 Pharmaceutics
06001015 Productos farmacéuticos / medicamentos